Viridian: Positive Interim Data in Phase 1/2 Thyroid Eye Disease Trial

 Clinial and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation -

- Full 10 mg/kg cohort data presented at ATA, 20 mg/kg and 3 mg/kg cohort data on track for 4Q22 -

- Pivotal program for VRDN-001 in TED patients set to begin this quarter -

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, presented positive proof-of-concept data from the 10 mg/kg cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). These data, as well as new in vitro data further characterizing and differentiating the pharmacological profile of VRDN-001, were included as part of three late-breaking poster presentations at the American Thyroid Association (ATA) 91st Annual Meeting. The abstract describing new in vitro data on the distinct anti-IGF-1R profile of VRDN-001 was also selected as an oral highlighted late breaking presentation. The three posters are available on the Viridian website (click here).

https://finance.yahoo.com/news/viridian-presents-positive-clinical-data-180400445.html